GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fangzhou Inc (HKSE:06086) » Definitions » EBITDA

Fangzhou (HKSE:06086) EBITDA : HK$-918 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Fangzhou EBITDA?

Fangzhou's EBITDA for the six months ended in Jun. 2024 was HK$-880 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-918 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

Fangzhou's EBITDA per Share for the six months ended in Jun. 2024 was HK$-0.66. Its EBITDA per share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.69.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.


Fangzhou EBITDA Historical Data

The historical data trend for Fangzhou's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fangzhou EBITDA Chart

Fangzhou Annual Data
Trend Dec21 Dec22 Dec23 Dec24
EBITDA
-355.09 -407.25 -191.14 -910.31

Fangzhou Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24
EBITDA Get a 7-Day Free Trial - -167.50 -45.86 -880.17 -37.40

Competitive Comparison of Fangzhou's EBITDA

For the Pharmaceutical Retailers subindustry, Fangzhou's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fangzhou's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Fangzhou's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Fangzhou's EV-to-EBITDA falls into.


;
;

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Fangzhou's EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Fangzhou's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2023, Fangzhou's EBITDA was HK$-191 Mil.

Fangzhou's EBITDA for the quarter that ended in Jun. 2024 is calculated as

Fangzhou's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Jun. 2024, Fangzhou's EBITDA was HK$-880 Mil.

EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-918 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Fangzhou  (HKSE:06086) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Fangzhou EBITDA Related Terms

Thank you for viewing the detailed overview of Fangzhou's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Fangzhou Business Description

Traded in Other Exchanges
N/A
Address
4th Street, Floor 1-2, Building S, Kehui Jingu, No. 99, Science Avenue, Luogang Science City, Huangpu District, Guangdong Province, Guangzhou, CHN
Fangzhou Inc is a online chronic disease management platform in China. It has focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. The company provide comprehensive medical services and online retail pharmacy services through Jianke Platform. The principal segment of the group are online retail pharmacy services, comprehensive medical services and customized content and marketing solutions. Key revenue is generated from Online retail pharmacy services.
Executives
Asia Tech Holdings Limited 2201 Interest of corporation controlled by you
Vistra Trust (hong Kong) Limited 2301 Trustee
Crescent China Investment Management Ltd. 2102 Investment manager
Hand David Mckee 2201 Interest of corporation controlled by you
Rojanavanichkul Danai 2201 Interest of corporation controlled by you
Veneto Holdings Ltd. 2201 Interest of corporation controlled by you
Tech-med Cayman Iii Ltd. 2201 Interest of corporation controlled by you
Tech-med Investments (s) Pte. Ltd. 2101 Beneficial owner
Cp Pharmatech Singapore Pte. Ltd. 2101 Beneficial owner
Asia Tech Investments Ltd. 2101 Beneficial owner
Crescent Acso Investment Management Ltd 2201 Interest of corporation controlled by you
Crescent Trident Singapore Pte. Ltd. 2101 Beneficial owner
Xie Fangmin 2201 Interest of corporation controlled by you
Zhou Feng 2201 Interest of corporation controlled by you
Fangrong Management Limited 2101 Beneficial owner

Fangzhou Headlines

No Headlines